INTRODUCTION
The p53 tumor suppressor gene is believed to play an important role in neuronal cell death in acute neurological disease (1) (2) (3) (4) (5) (6) and in neurodegeneration (7) . Studies have demonstrated that p53 protein levels are upregulated following excitotoxicity, hypoxia, and ischemia (2, 3, 8) and that forced upregulation of p53 alone is sufficient to cause neuronal cell death (5, (9) (10) (11) . Consistent with this, mice carrying a p53 null mutation exhibit reduced brain damage following excitotoxicity and stroke (5, 6, 12) . Finally, recent studies have shown that p53 blocking peptides are neuroprotective following acute brain injury and may serve as potential therapeutic agents (13) . Taken together, these studies demonstrate the importance of p53 as a key apoptotic factor following neuronal injury and underscores the necessity to uncover the mechanisms by which p53 induces the death of postmitotic neurons.
The p53 signaling cascade is complex and it has become increasingly clear that the mechanisms by which p53 induces apoptosis vary depending on the tissue type (reviewed by Prives and Hall (14) ). For example, recent studies have demonstrated that in certain cell types, p53 can induce apoptosis exclusively at the mitochondrial level through direct interaction with Bcl2 family proteins (15) . In contrast, other cell types such as postmitotic neurons exposed to DNA damaging agents require the transcriptional activation domain of p53 for death to occur (Cregan et al. unpublished) . In postmitotic neurons, we and others (16) (17) (18) have demonstrated that p53-mediated cell death involves a Bax-dependent, caspase3 activation involving induction of APAF1. In proliferating cells, Bax was shown to be a direct target for p53 (19) , however no significant p53-mediated Bax upregulation was found in neurons (16, 17, 20) . While we have found that p53 transcriptional activity is essential for the induction of neuronal cell death, the downstream targets responsible for Bax activation remain unknown. To identify the regulatory targets by which p53 induces neuronal cell death, we conducted DNA microarray analysis using postmitotic neurons undergoing p53-mediated apoptosis. Using this approach, we and others have previously identified Apaf1 as a key intermediate in the apoptotic signaling cascade that is directly activated by p53 (21) (22) (23) . We have now used DNA microarray analysis to identify p53 target genes involved in neuronal injury and have consistently found a striking induction of the proapoptotic gene, SIVA.
SIVA is a proapoptotic protein that was originally identified through its association with the cytoplasmic tail of CD27, a member of the tumor necrosis factor receptor (TNFR) superfamily (24) (25) (26) (27) . CD27 lacks a death domain thus yeast-2-hybrid assays were performed to identify the mechanism by which CD27 may induce apoptosis (28) (29) (30) (31) .
SIVA, the CD27-interacting protein was found to contain a death domain (DD) homology region, a box-B-like ring finger, and a zinc finger-like domain (27) . More recently SIVA was also found to interact with an additional TNFR family protein, GITR (32) . Consistent with its structural domains, forced expression of SIVA has been shown to induce apoptosis when expressed in a number of different cell lines (27) .
In addition to its interaction with TNFR superfamily members, SIVA has also been shown to interact with anti-apoptotic Bcl-2 family members (33) . There are two SIVA splice variants, SIVA-1 and SIVA-2, of which SIVA-1 retains exon2 which is believed to 5 be critical for apoptotic activity (34) although a recent study suggests that both splice forms can induce apoptosis in a similar fashion (35) . Exon2 is comprised of an amphipathic helical structure, known as the SAH domain, which is structurally similar to the BH3 domain of Bcl-2 family proteins (33) . Consistent with an endogenous interaction with Bcl-2 family proteins, SIVA has been localized to the cytoplasm and mitochondria and was recently shown to directly bind to Bcl-X L through this amphipathic domain.
Mutation of the SAH domain prevents interaction with anti-apoptotic Bcl-2 family proteins and abrogates its ability to induce apoptosis (33) . This, as well as studies demonstrating interactions with TNFR family proteins, suggests that SIVA may function through multiple mechanisms which may be dependent on the cell type and apoptotic stimulus. Consistent with a key role in regulating apoptosis in tumor cells, SIVA is upregulated in response to UV radiation and oxidative stress in a number of cell types (33, 36) . Recently, SIVA was identified through DNA microarray analysis as a p53-induced and DNA damage-induced gene following treatment of colon carcinoma cells with a topoisomerase I inhibitor (37) . In addition, examination of certain types of cancer has revealed a down regulation of the SIVA gene along with p53 suggesting that SIVA itself may have a potential role as a tumor suppressor due to its proapoptotic function (38) .
The role of the proapoptotic gene, SIVA, in regulating the death of neuronal cells has not yet been explored. Using DNA microarray analysis to identify p53 target genes involved in neuronal cell death, we have identified SIVA as a p53 target. In addition to its proapoptotic role in the immune system and in tumor cells, we now demonstrate that SIVA also functions in injury-induced apoptosis of postmitotic neurons. By isolation and analysis of the SIVA promoter, we have identified response elements for both E2F1 and p53. Like p53, E2F1 is a tumor suppressor gene (39, 40) involved in the regulation of apoptosis and its involvement has been demonstrated in a number of neuronal injury models (41) (42) (43) (44) (45) (46) (47) . We have identified E2F consensus sites in the promoter region while recognition sequences for p53 were found in the first intron. Furthermore, these consensus sites are also conserved in the human SIVA gene where E2F sites were also located within the promoter and p53 sites were again found in the first intron.
Electrophoretic mobility shift assays revealed that both transcription factors are capable of binding their putative consensus sites, and luciferase reporter assays revealed that E2F1 and p53 can activate transcription of the SIVA promoter at these sites. Here, we report that the proapoptotic gene SIVA, is a direct transcriptional target for both tumor suppressors, p53 and E2F1.
cDNA for SIVA was a kind gift from Dr. Kanteti V.S. Prasad (27) . cDNA for wild type p53, p53-∆V (deletion of conserved box V: residues 270-286), and p53-173L (point mutation at residue 173 to Leu) were kind gifts from Dr. Karen Vousden (50, 51) . The p53 double transactivation mutant, p53-DM (mutations L22E, W23S, W53F and E54S), was a kind gift from Dr. Xinbin Chen (52) . Recombinant adenoviral vectors carrying the SIVA-GFP, GFP, and wild type or mutant p53 expression cassettes were constructed, purified, and titred as described previously (53) . Prior to use, all recombinant adenovirus vectors were tested and confirmed to be wild type free. All experiments were performed at a MOI of 50 pfu/cell. Recombinant adenoviral vectors were added to cell suspensions immediately before plating for primary neuronal cultures and 24 hours following plating for progenitor cell cultures. Cortical neurons were treated with 10µM camptothecin (Sigma-Aldrich) 2 days after plating. For viability tests the colorimetric MTT survival assay (Cell Titer Kit, Promega, Madison, WI) that measures the mitochondrial conversion of the tetrazolium salt to a blue formizan salt was used as described previously (9) .
DNA microarray analysis
For p53 microarray analysis, cortical neurons were infected at a multiplicity of infection 
Surgical procedures
All animal procedures conformed to guidelines endorsed by the Canadian Institutes of Health Research and were approved by the Animal Care Committee of the University of Ottawa. Male C57BL/6 mice (Jackson Laboratories, Bar Harbour, ME) weighing 20-22 g were subjected to 2 hours of middle cerebral artery occlusion as previously described (23) . Following reperfusion for 48 or 72 hours, brains were removed and the striatum and cortex from the ipsilateral and contralateral sides were dissected separately and tissue was flash frozen using liquid nitrogen prior to protein extraction.
Semiquantitative RT-PCR analysis
Total RNA was isolated from cells using Tripure isolation reagent according to the manufacturer's instructions (Roche Diagnostics). Pilot experiments were done to determine the linear range of amplification with respect to quantity of starting template and PCR cycles using mouse specific primers: SIVA forward 5'-CGCCCATCGCTTG TTCATCGTG-3' and SIVA reverse 5'-CCGCAGCCCCAGCAGGTGTAT-3'. 6-12 ng of total RNA was used for cDNA synthesis and targeted gene amplification using the SuperScript One-Step RT-PCR kit (Invitrogen Canada Inc., Burlington, ON). cDNA synthesis was carried out at 50°C for 30 min followed by a 2 min initial denaturation step at 94°C. This was followed by 35 cycles (SIVA) or 25 cycles (GAPDH) at 94°C for 30 s, 54°C for 30 s, and 72°C for 1 min. Primers were designed to amplify nucleotides 329-437 of the SIVA transcript and 139-740 of the GAPDH transcript. The resulting product was sequenced and confirmed to be SIVA.
Western blot analysis
Western blot analysis was performed as described previously (17) with antibodies against p53 (1C12, Cell Signaling Technology, Beverly, MA) and β-actin (SC-1616, Santa Cruz Biotechnologies, Santa Cruz, CA) as a loading control.
Electrophoretic Mobility Shift Assay
EMSAs were performed on total protein extracts as described (23) Furthermore, supershifts were performed with a p53-specific antibody FL393 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and an E2F1-specific antibody C20-X (Santa Cruz Biotechnology, Inc.). Complexes were resolved on a 5% polyacrylamide, 1x Tris-Glycine gel, dried, and visualized by autoradiography.
SIVA promoter luciferase reporter assays
The SIVA luciferase reporter construct (pGL3b-SIVA) was generated by subcloning a murine SIVA gene fragment (-440 to +1770) containing the putative promoter, exon1 and intron1 into the Sma1 site of pGL-3 basic (Promega). P53 binding site deletion constructs were generated by excising p53-BS1 (+752 to +780) with BsmB1 and PvuII, p53-BS2 wells with 200 µL/well of 1X reporter lysis buffer (Promega). Cells were collected by scraping and were subjected to one freeze-thaw cycle followed by centrifugation.
Supernatants were collected and assayed for luciferase activity using a BioOrbit 11250 luminometer. A portion of the harvested cell extract was assayed for β-galactosidase 
RESULTS

SIVA is induced during p53-mediated neuronal cell death
While previous studies in proliferating cells have identified Bax as a direct transcriptional target for p53 (19) , we and others have found no induction of Bax in response to p53 in postmitotic neurons (16, 17, 20) . Presently, little is known regarding the molecules that regulate neuronal cell death in the p53 apoptotic cascade. To identify the mechanism by which p53 induces the death of postmitotic neurons, DNA microarray analysis was performed using Affymetrix gene chip arrays. This analysis was conducted in primary cortical neurons by direct p53 overexpression using adenoviral vector mediated gene delivery of a GFP control vector (Ad-GFP), wild type p53 (Ad-p53), a transactivation defective mutant (Ad-p53-DM) and a p53 DNA-binding mutant (Ad-p53-∆V) that fails to induce apoptosis. To verify the reliability of the GeneChip data, three known p53
responsive genes were used as a basis for comparison including APAF1 (21,23), PERP (54) , and Bax (19) . Evaluation of previously characterized p53 responsive genes revealed a reproducible 3.5 fold induction of APAF1, a 6.8 fold increase in PERP but no significant change in Bax mRNA expression in neurons expressing wild type p53 (Table   1) . Furthermore, no induction of SIVA mRNA was found in response to mutant p53 lacking either the DNA binding domain or both transactivation domains. These data suggest that SIVA may serve as an important p53 target gene involved in several injuryinduced modes of neuronal cell death.
To confirm results obtained with DNA microarray analysis, we examined SIVA mRNA levels by reverse transcription (RT)-PCR under similar conditions. Consistent with DNA microarray data, primary cerebellar granule neurons infected at 50 MOI with Ad-p53 exhibited a significant increase in SIVA mRNA levels relative to cells infected with AdLacZ (Fig. 1A) . This increase in SIVA mRNA levels was evident as soon as p53 became stably expressed, usually at 36 -48 hours following Ad-p53 infection (results not shown).
To verify that SIVA could also be upregulated in response to endogenous p53 activity,
we treated cortical neurons with 10 µM camptothecin a DNA-damaging agent that has been shown previously to induce p53-dependent death (16) . Cortical neurons treated with camptothecin responded with a rapid increase in p53 protein that was first detectable at 2 hours and continued to increase for 4 hours after which the levels became stabilized.
( Fig.1B) In wild type neurons, camptothecin caused SIVA induction as early as 6 hours following treatment demonstrating that SIVA upregulation is an early event in the apoptotic cascade co-incident with the increase in p53 protein (Fig.1C ). This induction, however, was not observed in p53-deficient cells treated under identical conditions (Fig.   1C ). Finally, to ask whether SIVA induction occurs in vivo following neuronal injury in which the involvement of endogenous p53 has previously been demonstrated (3,55) , we examined the brains of mice subjected to a model of focal ischemia. Brains were removed from mice subjected to 2 hours middle cerebral artery occlusion followed by 48 and 72 hours of reperfusion. This procedure generates an infarct in the striatum and cortex on the side of the brain ipsilateral to the occluded middle cerebral artery. Extracts from brain tissue revealed that SIVA mRNA is induced in the affected ipsilateral forebrain relative to the control tissue obtained from the contralateral hemisphere (Fig.1D) .
Together, these results indicate that increased levels of SIVA transcript correlate directly with p53 activation and suggest the possibility that this proapoptotic gene may be a direct transcriptional target of p53 in the regulation of neuronal cell death.
Upregulation of SIVA is sufficient to induce cell death in neural precursor cells and postmitotic neurons
Before exploring the possibility that p53 may directly activate the SIVA gene, we first Fig.2A) . Similarly, increased expression of SIVA was also sufficient to induce the death of neural precursor cells treated under identical conditions (Fig. 2B) . to -372 bp and -296 to -280 bp and two putative p53 consensus sequences (57) within intron 1 at 752 to 780 bp and 897 to 917 bp (Fig. 3A) . These are referenced from the transcription start site (+1) which refers to the longest published sequence of SIVA (GenBank accession no. AF033114). Since the SIVA gene exhibited a striking induction during p53-mediated neuronal apoptosis, we assayed whether p53 was able to bind the consensus sites and activate transcription on the SIVA promoter. Oligonucleotides corresponding to the p53 consensus sites were synthesized and electrophoretic mobility shift assays (EMSAs) were performed. Protein was extracted from neurons 48 hours following adenovirus-mediated p53 delivery. The EMSA demonstrates that neuronal extracts exhibit p53-DNA binding activity at both putative binding sites (Fig. 3B) . The specificity of p53 binding at these consensus sites was supported by two control experiments: (a) DNA binding activity could be competed out by incubation with excess unlabeled probes; and, (b) the complexes were supershifted by the addition of a p53-specific antibody. The results of these experiments demonstrate that p53 can bind the two p53 consensus sites in the first intron of the SIVA gene.
p53 can activate transcription from the SIVA promoter
While the above experiments demonstrate that p53 can directly bind the putative consensus sequences, we next asked whether p53 binding could activate transcription from the SIVA promoter. To test this, primers were designed to isolate 550 bp's of the SIVA promoter as well as exon1 and intron1 which contains the p53 response elements.
This insert was isolated by PCR and cloned into the pGL3b luciferase reporter plasmid.
To examine whether p53 could directly activate transcription, four different SIVAluciferase reporter constructs were tested ( Figure 4A ), including: the full length SIVA insert (pGL3b-SIVA), a truncated insert missing the first p53 consensus sequence (pGL3b-SIVA-∆BS1), a truncated insert missing the second p53 recognition sequence (pGL3b-SIVA-∆BS2); and a truncation deleting both proposed p53 recognition sequences (pGL3b-SIVA-∆∆). Cultured SN48 neuronal cell lines were transfected with one of the SIVA promoter/luciferase constructs, a plasmid containing PGK-LacZ to control for transfection efficiency, and one of following plasmids containing wild type p53, mutant p53 or empty vector. Cells cotransfected with the intact SIVA luciferase construct (pGL3b-SIVA) and wild type p53 exhibited a dramatic 12 fold increase in luciferase activity (Fig. 4B ). As controls, we used p53 mutants that failed to induce SIVA mRNA, based on DNA microarray analysis (Table 1) . In contrast to wild type p53, there was no induction of luciferase activity following cotransfection with the DNA binding mutant p53-173L or the double mutant (p53-DM) lacking both transactivation domains of p53 (Fig.4B) . To determine the responsiveness of the individual p53 DNA binding sites, cells
were cotransfected with each of the SIVA promoter constructs carrying deletions in the p53 consensus sites together with an expression vector for wild type p53. Deletion of p53-BS1 exhibited a 35% reduction in luciferase activity, however, still retaining activity.
In contrast, deletion of p53-BS2 alone or deletion of both binding sites revealed complete loss of p53 responsiveness (Fig.4C) . From these results, we conclude that the SIVA gene is a direct transcriptional target for p53, and of the two p53 consensus sites, BS2 is the most important to confer p53 responsiveness.
SIVA is directly induced by E2F1
Since putative E2F response elements were found on the SIVA promoter and E2F1 has previously shown to be a key proapoptotic protein involved in neuronal injury (41-47),
we asked whether E2F1 could also directly modulate transcription of the SIVA gene in neurons. We first addressed whether E2F1 had any effect on SIVA1 mRNA levels by conducting DNA microarray analysis and RT-PCR. Consistent with previous results, E2F1 induced mRNA expression for c-Myb (10.5 fold), DHFR (7.9 fold), caspase3 (2.9 fold), and APAF1 (2.5 fold). In addition, our results revealed a 2.8 fold induction of SIVA1 mRNA in response to E2F1 (Table 2) . Results from DNA microarray analysis were confirmed by RT-PCR which also demonstrated a dramatic induction of SIVA-1 mRNA in response to E2F1 (Fig.5A ). To ask whether E2F1 was capable of binding the SIVA-1 promoter at the two consensus sequences, EMSA was performed as for p53. Our results show that E2F1 is capable of binding both consensus E2F sites on the SIVA promoter (Fig.5B) . Again, specificity was confirmed by competition with unlabelled probe and supershift with an E2F1 specific antibody. While our results demonstrate that E2F1 could bind the E2F consensus sites on the SIVA promoter, we next examined whether E2F1 could activate transcription. Luciferase reporter assays were performed with the -440 to 1771 bp fragment containing the SIVA promoter, the first exon and intron as described above as well as the luciferase construct pGL3b-SIVA-∆∆ missing both p53 DNA consensus binding sequences. SN48 cells were cotransfected with pGL3b-SIVA or pGL3b-SIVA-∆∆ along with expression plasmids for E2F1 or empty control vector, and LacZ. Our assays revealed that E2F1 was capable of inducing a 2.6 fold activation of the SIVA promoter relative to the control vector alone (Fig. 5C ). Deletion of both p53 consensus binding sites from the luciferase construct did not alter the ability of E2F1 to induce luciferase activity from the SIVA promoter demonstrating that SIVA can be regulated independently of p53. Based on our findings that: E2F1 can induce SIVA mRNA in neurons, the SIVA promoter contains E2F consensus sequences, E2F1 is capable of binding these sites, and that the SIVA promoter is activated 2.6 fold by E2F1, we conclude that SIVA is also a direct transcriptional target for E2F1 in postmitotic neurons.
E2F1 and p53 regulatory elements are conserved in the human SIVA gene.
Similar to the mouse, analysis of the promoter region of the human SIVA gene with the Genomatix software revealed four E2F consensus binding sequences but no p53 binding sites in the promoter region (Fig. 6A ). Further analysis of the human Siva gene also uncovered putative p53 consensus binding sequences in introns 1, 2 and 3 ( Fig. 6B) which are also similar to those found in mouse genomic DNA. and mice lacking E2F1 show significant protection from stroke injury (64) . Since stroke injury has been shown to involve both E2F1 and p53, it is not surprising that we find a significant induction of SIVA gene expression in brains following focal ischemia.
Interestingly, the presence of both E2F and p53 response elements on the promoter of a proapoptotic gene has been previously shown. Moroni et al. have demonstrated that the promoter of APAF1 is regulated by both p53 and E2F1 (21) . Recently, the BH3-only proteins PUMA and Noxa known to be direct p53 targets, have also been shown to be regulated by E2F1 (66). It appears that genes like APAF1, PUMA, Noxa and SIVA are part of a growing list of genes that may be important in regulating the death response initiated by these tumor suppressors.
E2F1-mediated apoptosis is thought to proceed through both p53-dependent and p53-independent pathways. Thus, the potential for the convergence of both the p53 and E2F1
pathways to induce neuronal cell death exists following brain injury. Recent research, in proliferating cells, has demonstrated that E2F1's interaction with the p53 pathway could involve transcriptional upregulation of E2F1 target genes such as p14/p19ARF which affect p53 accumulation (67, 68) , E2F1-induced phosphorylation of p53 (69) or direct E2F1-p53 complex formation (70) are all believed to enhance the apoptotic activity of p53. In neurons, SIVA regulation could be complemented by this synergy between E2F1
and the p53 pathways. Not all models of neuronal cell death, however, require both pathways. β-amyloid-evoked neuronal cell death, which is mediated by E2F1, does so in a p53-independent manner (45) . We have also shown here that following DNA damage, SIVA is not upregulated in p53-deficient neurons. Western blot analysis demonstrated that E2F1 was not induced at early timepoints following treatment with camptothecin and was only upregulated after 16 hrs, long after apoptotic events have been initiated (data not shown). These results suggest that E2F1 is not involved in the regulation of SIVA in this model of neuronal injury. Whether SIVA regulation is an independent event or a consequence of cross talk between these two apoptotic pathways is likely a function of the initiating mechanism.
While SIVA has been shown to play a role in regulating apoptosis through the TNFR signaling cascade, the involvement of SIVA in neuronal injury has not yet been described. SIVA contains a death domain and therefore functions in TNFR signaling in cells of the immune system (27) . More recently SIVA has also been shown to interact with GITR, another member of the TNFR superfamily expressed in T cells. Although SIVA was first characterized in cells of the immune system and was thought to be involved in T cell homeostasis, expression analysis revealed that SIVA is expressed in most tissues (34) . In addition to normal tissues, SIVA is also expressed in tumor cells exposed to genotoxic agents that induce a p53 death response. Since CD27 is expressed primarily in T and B cells, the mechanism by which SIVA signals apoptosis in other cell types such as neurons or tumor cells remains unknown. Presently, it is unknown whether SIVA interacts with any TNFR family members expressed in the nervous system. There are a number of TNFR subtypes expressed in CNS neurons, including TNFR1, p55-TNFR, TNFRII and the p75 low affinity neurotrophin receptor (71) . It has also been reported that TNF signaling is increased in stroke and is believed to have a major impact on the extent of brain injury (71, 72) . Based on studies in the immune system it is likely that SIVA may also be involved in TNF signaling following injury, however the interacting TNF targets in the CNS remain unknown.
In addition to interactions with members of the TNFR super family, SIVA-1 has also been shown to directly interact with antiapoptotic members of the Bcl-2 family proteins.
SIVA has no BH3-like domain however the site of interaction with Bcl-X L was found to be through a 20 amino acid long amphipathic helix known as the SAH domain (33) .
Disruption of this interaction by mutation of this site mitigated the apoptotic response.
Thus, it is believed that SIVA may induce cell death by sequestering anti-apoptotic Bcl-2 family proteins and thereby allowing the proapoptotic family members to function. The molecules with which SIVA interacts to induce apoptosis may vary depending on the cell type and future studies should elucidate its mechanism of action in the CNS.
In summary, SIVA is a proapoptotic gene that is expressed in a broad scope of tissues including cells of the immune system, tumor cells and in the CNS. SIVA is induced in response to p53 and E2F1, two tumor suppressor genes that function in cell cycle regulation and apoptosis. Upregulation of SIVA in itself is sufficient to induce the apoptotic cascade implicating its importance in injury induced apoptosis. Indeed, a number of tumor tissues have revealed significantly low levels of SIVA suggesting that SIVA may also play an important role in protection against cancer. By isolation of the mouse SIVA promoter we have identified consensus binding sites for both p53 and E2F1
and shown that these factors are able to bind their respective sites. Moreover, we have shown that p53 and E2F1 binding can activate the SIVA promoter demonstrating that SIVA is a direct transcriptional target for these tumor suppressor genes. Presently, a SIVA-deficient mouse has not been developed, however, future studies involving deletion of SIVA will reveal the extent of its involvement in different modes of cell death. The fact that SIVA is highly induced by p53 and E2F1 in a broad spectrum of cell types, and that SIVA upregulation is sufficient to induce the death cascade, speaks to its importance not only in protection against tumorigenesis but also in brain damage following acute injury. 
